Who we are
Of the estimated 7,000 known rare diseases, less than 10% have an available treatment option. Our mission is to reduce the impact of rare and devastating diseases by providing urgently needed medicines.
We believe that each person with a rare disease has the right to the best treatment, and we are dedicated to providing this across a range of therapeutic areas. Our core therapy areas include Endocrinology, Oncology and Metabolic.
At Recordati Rare Diseases we have almost 20 years of experience in bringing treatments to those who suffer from little known conditions, including orphan and ultra-orphan diseases.
In the 19th century the Recordati family began a small pharmacy, in Correggio, Northern Italy, serving their local community. In 1926, Giovanni Recordati moves from experimenting in the back of that same pharmacy, to founding a company at 28 years old “Laboratorio Farmacologico Reggiano”.
Recordati – The first 100 years
One hundred years later, in 2026, Recordati stands as a global pharmaceutical group with a presence in over 150 countries, committed to unlocking the full potential of life. Recordati centenary is not just a celebration of longevity—it is a confirmation of Recordati’s purpose, values, continuity and care.
Recordati honours the legacy of the people, patients and partners who shape its journey, and embrace the responsibility of shaping the next hundred years.
We work alongside global networks of patients, patient groups, experts, healthcare professionals, scientists, policy makers and regulators to educate communities and improve access.
We are a global leader in rare diseases. We are in around 150 countries and continue to expand our footprint, operations and the number of patients we treat.
We are continuously committed to activities and initiatives within disease communities which support awareness and better research in areas of need, particularly within rare diseases.
Recordati continuously develops new specialties originating either internally or acquired through development agreements with other pharmaceutical companies and research institutes.
Commitment, scientific rigour, capability and highly specialized personnel allow the Group to develop new treatments and to build an innovative product pipeline.
MILESTONES
Giovanni Recordati founds the Laboratorio Farmacologico Reggiano in Correggio (RE, Italy)
Transfer of headquarters to Milan
Recordati – Syntex (now part of Roche) licence agreement. Located in Silicon Valley, Syntex was a pioneering company in the study and synthesis of steroid hormones
Inauguration of the pharmaceutical chemical plant in Campoverde di Aprilia
Listing on the Italian Stock Exchange
Beginning the process of internationalisation – Establishment of a subsidiary in Spain, now called Casen Recordati
Acquisition of Doms Adrian (France)
Acquisition of Bouchara (France)
Establishment of Bouchara Recordati in France
- Acquisition of Merckle Recordati in Germany, now Recordati Pharma
- Establishment of Recordati Pharmaceuticals in the United Kingdom
- Establishment of Recordati Hellas in Greece
- Establishment of the new pharmaceutical chemical plant in Cork, Ireland
Acquisition of the Grupo Jaba companies in Portugal, today Jaba Recordati
Entry to the rare diseases sector with the acquisition of Orphan Europe, now Recordati Rare Diseases
- Acquisition of FIC and FIC Médical, dedicated to the registration and promotion of pharmaceutical products in Russia and other Commonwealth of Independent States (C.I.S.) countries
- Acquisition of Yeni Ilaç in Turkey, today Recordati Ilaç
Acquisition of Herbacos-Bofarma in the Czech Republic and Slovakia, today Herbacos Recordati
Acquisition of ArtMed International in Romania, now Recordati Romania
Acquisition of Dr. F. Frik Ilaç in Turkey, now Recordati Ilaç
- Entry into the US market rare diseases sector
- Acquisition of product portfolio for the treatment of a number of rare diseases in the US
- Acquisition of Farma-Projekt in Poland, now Recordati Polska
- Acquisition of Opalia Pharma and its cGMP certified production facilities in Tunisia, now Opalia Recordati
- Acquisition of Laboratorios Casen Fleet and its cGMP certified production facilities in Spain, now Casen Recordati
Establishment of new subsidiaries in Brazil, Mexico and Colombia
- SPC and OTC portfolio strengthened
- Acquisition of Italchimici in Italy
- Acquisition of Pro Farma AG, now Recordati AG, in Switzerland and Austria
- Acquisition of Natural Point in Italy
- Acquisition of Tonipharm in France
- Establishment of new subsidiaries in Japan and Australia
- Expansion of the rare diseases product portfolio: entry into the endocrinology sector
- Establishment of Recordati Bulgaria
- Acquisition of EUSA Pharma (UK) Ltd, a global specialist pharmaceutical company focused on rare diseases and niche oncology
- Agreement with GSK to commercialize Avodart® (dutasteride) and Combodart®/Duodart®
- Agreement with Sanofi to acquire the global rights to Enjaymo®, strengthening our rare diseases franchise
- License and supply agreement with Amarin to commercialise Vazkepa® strengthening our cardiovascular franchise
